Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-AXL, Ab-2 Vector   (CAT#: GTVCR-WQ139MR)

This product GTVCR-WQ139MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting AXL. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Humanized
RefSeq NM_001278599.2
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 558
UniProt ID M0R0W6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-AXL, Ab-2 Vector (GTVCR-WQ139MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ1017MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL6, CNTO 136 Vector Vector CNTO 136
GTVCR-WQ1925MR IVTScrip™ pSP6-VEE-mRNA-Anti-MET, MetMAb Vector Vector MetMAb
GTVCR-WQ2434MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL13&IL4, SAR156597 Vector Vector SAR156597
GTVCR-WQ1754MR IVTScrip™ pSP6-VEE-mRNA-Anti-SOST, LY2541546 Vector Vector LY2541546
GTVCR-WQ835MR IVTScrip™ pT7-VEE-mRNA-Anti-GP, c2G4-N Vector Vector c2G4-N
GTVCR-WQ2174MR IVTScrip™ pSP6-VEE-mRNA-Anti-TNF, PEG sTNF-RI Vector Vector PEG sTNF-RI
GTVCR-WQ2008MR IVTScrip™ pT7-VEE-mRNA-Anti-ERBB3, MM-121 Vector Vector MM-121
GTVCR-WQ1690MR IVTScrip™ pSP6-VEE-mRNA-Anti-FN, L19TNF Vector Vector L19TNF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW